RDUS - Radius Health, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Radius Health, Inc.

950 Winter Street
Waltham, MA 02451
United States

IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees398

Key Executives

NameTitlePayExercisedYear Born
Mr. Jesper HøilandPres, CEO & Director1.05MN/A1960
Mr. Jose CarmonaCFO, Sr. VP & Treasurer673.46kN/A1972
Mr. Joseph KellySr. VP of Sales & Marketing654.33kN/A1969
Dr. Charles Q. MorrisChief Medical Officer414.09kN/A1965
Dr. Stavros C. ManolagasCo-Founder & Member of the Scientific Advisory BoardN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke University; and Teijin Limited. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Radius Health, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 6; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.